Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; ther...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: Millar, John S., Reyes-Soffer, Gissette, Jumes, Patricia, Dunbar, Richard L., deGoma, Emil M., Baer, Amanda L., Karmally, Wahida, Donovan, Daniel S., Rafeek, Hashmi, Pollan, Laura, Tohyama, Junichiro, Johnson-Levonas, Amy O., Wagner, John A., Holleran, Stephen, Obunike, Joseph, Liu, Yang, Ramakrishnan, Rajasekhar, Lassman, Michael E., Gutstein, David E., Ginsberg, Henry N., Rader, Daniel J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2015
Témata:
Clinical Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497759/
https://ncbi.nlm.nih.gov/pubmed/25961461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI80025
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky